Publication Name	World Journal of Hematology
Manuscript ID	20289
Country	Japan

Received	2015-06-01 16:00
Peer-Review Started	2015-06-04 08:36
First Decision by Editorial Office Director
Return for Revision	2015-08-22 17:40
Revised	2015-09-06 07:47
Publication Fee Transferred
Second Decision by Editor	2015-09-28 14:35
Second Decision by Editor-in-Chief	2015-09-28 15:00
Final Decision by Editorial Office Director	2015-10-13 17:13
Articles in Press	2015-10-13 17:13
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-02 19:22
Publish the Manuscript Online	2015-11-12 11:17

ISSN	2218-6204 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis: Study protocol of a prospective pilot study
Manuscript Source	Invited Manuscript
All Author List	Shinsaku Imashuku
Funding Agency and Grant Number
Corresponding Author	Shinsaku Imashuku, MD, PhD, Depart­ment of Laboratory Medicine, Uji-Tokushukai Medical Center, 145 Ishibashi, Makishima-cho, Uji 611-0042, Japan. shinim95@mbox.kyoto-inet.or.jp
Key Words	Hemophagocytic lymphohistiocytosis; Epstein-Barr virus; Immune-chemotherapy; Rituximab; Hematopoietic stem cell transplantation
Core Tip	Diagnosis of Epstein-Barr virus-related hemo-phagocytic lymphohistiocytosis (EBV-HLH) must fulfill both the evidence of EBV infection and the diagnostic criteria for HLH. EBV-HLH is heterogeneous. The majority of EBV-HLH occurs in apparently immuno-com-petent subjects, but some are associated with chronic active EBV infection status, X-linked lymphoproliferative disease or with familial HLH. Thus, treatment and outcome differ significantly depending on the underlying disease. To find out a most appropriate treatment, various laboratory tests are required to clarify the underlying diseases.
Publish Date	2015-11-12 11:17
Citation	Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis: Study protocol of a prospective pilot study. World J Hematol 2015; 4(4): 69-75
URL	http://www.wjgnet.com/2218-6204/full/v4/i4/69.htm
DOI	http://dx.doi.org/10.5315/wjh.v4.i4.69

Full Article (PDF)	WJH-4-69.pdf
Full Article (Word)	WJH-4-69.doc
Manuscript File	20289-Review.docx
Answering Reviewers	20289-Answering reviewers.pdf
Audio Core Tip	20289-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20289-Conflict-of-interest statement.pdf
Copyright License Agreement	20289-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	20289-Language certificate.pdf
Peer-review Report	20289-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	20289-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	20289-Scientific misconduct check.pdf
Scientific Editor Work List	20289-Scientific editor work list.pdf